Tag: pharmaceuticals
-
Stem Cells Created with Gene Editing
A research lab in San Francisco devised a simpler process for creating stem cells from skin cells in mice with the gene editing technique Crispr.
-
Limited Industry Progress Seen on Microbial Resistance
A pharmaceutical industry coalition documents some advances after 2 years in developing better products and practices against antimicrobial resistance, but progress is limited and uneven.
-
Technique Developed for High-Speed Antibody Screening
A process is being developed to quickly discover antibodies in a person’s immune system that can also lead to new vaccines and drugs against viruses.
-
Small Business Grant Advances Drug Safety Test System
An award from National Institutes of Health is advancing a technology for testing the safety of drugs with heart muscle cells derived from stem cells before the drugs are tested on humans.
-
FDA to Release More Accessible Clinical Trial Data
The U.S. Food and Drug Administration plans to make available in a more user-friendly format details from clinical trials of new drugs approved by the agency.
-
First MERS Virus Treatment Found Safe
An experimental treatment for Middle East respiratory syndrome, or MERS, infections made from antibodies produced in cattle is shown in a clinical trial to be safe for patients.
-
Stem Cell Patches Shown to Treat Heart Attack Damage
Human heart muscle patches made from stem cells helped fix damage and improve heart functions in tests with pigs induced with heart attacks.
-
HIV Drugs Formulated Into Once-Weekly Capsules
Medical and engineering researchers developed and tested in pigs a technique for packing several drugs into a capsule taken once a week to prevent and treat HIV infections.
-
Lilly, Tech Company Study Diabetes Experiences
A maker of diabetes drugs and digital health enterprise are beginning a study of real world experiences with self-management and education among people with diabetes.
-
Celgene Acquires Cancer Drug Start-Up in $7B Deal
The biopharmaceutical company Celgene Corp. is acquiring Impact Biomedicines Inc., a developer of drugs to treat a type of blood-related cancer, in a deal valued as much as $7 billion.